Financial Data and Key Metrics Changes - The company generated revenue of $665 million in Q1 2025, resulting in 4% organic growth, with a 1% headwind from foreign exchange [27][31] - Adjusted EPS for the quarter was $1.01, exceeding expectations of $0.93 to $0.95 [7][29] - Adjusted operating margins were reported at 25.6%, slightly up year-over-year and above expectations [28] Business Line Data and Key Metrics Changes - Life Sciences segment revenue was $340 million, up 1% reported and 2% organically, with low single-digit growth in pharma biotech customers and a decline in academic and government customers [32] - Diagnostics segment revenue reached $324 million, up 3% reported and 5% organically, driven by high single-digit growth in immunodiagnostics [33] Market Data and Key Metrics Changes - The Americas and Europe experienced mid-single-digit growth, while Asia saw low single-digit growth, with China also growing in low single digits [31] - U.S. academic customers, representing over 5% of total revenue, showed cautious spending due to uncertainties in funding [23][24] Company Strategy and Development Direction - The company is focused on maintaining strong organic growth and operational agility to navigate macroeconomic challenges [5][20] - A recent expanded alliance with Genomics England aims to enhance newborn genomic sequencing capabilities, positioning the company as a leader in this area [9] - The software business, representing about 8% of total revenue, grew over 20% organically in Q1 and is expected to continue strong growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's resilience and ability to adapt to changing market conditions, reaffirming a full-year adjusted EPS outlook of $4.9 to $5 [19][37] - The company anticipates a gross impact of approximately $135 million from tariffs, but expects to mitigate most of this through proactive measures [18][19] Other Important Information - The company repurchased $154 million of its shares in Q1, reducing the outstanding share count to 119.4 million [7][29] - The net debt to adjusted EBITDA leverage ratio was reported at 2.4 times, with all debt being fixed rate [30] Q&A Session Summary Question: Can you talk about the tariff impact and what products are affected? - Management indicated that they have been proactive in adjusting their supply chain to mitigate the $135 million gross tariff impact, focusing on products sold from the U.S. to China [41][43] Question: What are the expectations for the Life Sciences segment? - The Life Sciences segment is expected to see low single-digit growth, with instrumentation under pressure but solid growth in reagents [45][48] Question: How is the company managing its exposure in China? - The company expects low single-digit growth in China, with a slight decline in Life Sciences and mid-single-digit growth in Diagnostics [56] Question: What is the outlook for the software business? - The software business is expected to continue strong double-digit growth, with a focus on expanding into new markets [62][90] Question: What are the long-term margin expectations? - Long-term operating margin expectations remain unchanged, with a focus on SG&A volume leverage as growth continues [104]

Core Viewpoint - Revvity, Inc. reported strong first-quarter 2025 results with adjusted EPS of $1.01, exceeding estimates and showing year-over-year improvement [1][9] Financial Performance - Adjusted EPS of $1.01 beat the Zacks Consensus Estimate of 96 cents by 5.2% and improved 3.1% from the previous year [1] - Revenues reached $664.7 million, up 2.3% year over year and 4% organically, surpassing the Zacks Consensus Estimate by 0.4% [2] - GAAP EPS from continuing operations was 35 cents, compared to 21 cents in the prior-year period [1] Segment Analysis - Life Sciences segment revenues totaled $340 million, up 2% organically from the previous year, with adjusted operating income of $106 million, a 5% increase [3] - Diagnostics segment revenues were $324 million, reflecting a 3% year-over-year increase, with a 5% organic growth [3] Margin and Expense Analysis - Selling, general and administrative expenses were $249.7 million, down 4.2% year over year, while research and development expenses were $53.6 million, down 6.4% [5] - Adjusted operating income improved 2.5% to $169.9 million, with an adjusted operating margin of 25.6%, expanding 10 basis points [5] Financial Position - Cash and cash equivalents at the end of Q1 2025 were $1.14 billion, slightly down from $1.16 billion at the end of the previous quarter [6] - Net cash used in operating activities was $134.1 million, compared to $150.1 million in the year-ago quarter [6] 2025 Guidance - The company reiterated its earnings outlook, expecting adjusted EPS in the range of $4.90-$5.00, and updated revenue guidance to $2.83-$2.87 billion [7] - The previous revenue guidance was $2.80-$2.85 billion, with the Zacks Consensus Estimate for EPS and revenues at $4.93 and $2.82 billion, respectively [7] Market Reaction and Outlook - Shares of RVTY rose 5.9% in pre-market trading, although the stock has declined 14.6% year-to-date compared to the industry's 1.6% decline [9] - The company is well-positioned to navigate challenges and capitalize on opportunities, with solid execution across both segments [10] Recent Developments - The launch of EUROIMMUN's Anti-Measles Virus ELISA 2.0 in Europe is expected to drive additional sales [11] - FDA approval for the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test will facilitate commercialization in the U.S. market [12]

Financial Performance - Q1 2025 - Revenue reached $665 million, showing a 2% year-over-year increase[10] - Organic revenue growth was 4%, while foreign exchange had a negative impact of 1%[10] - Adjusted operating margin stood at 25.6%, a slight increase of 5 basis points year-over-year[10] - Adjusted EPS was $1.01, representing a 4% year-over-year increase[10] - Free cash flow was $118 million, with a free cash flow percentage of adjusted net income at 97%[10] Segment Performance - Q1 2025 - Life Sciences revenue was $340 million, with organic growth of 2%[12, 13] - Diagnostics revenue was $324 million, with organic growth of 5%[15, 16] Full Year 2025 Guidance - Revenue is projected to be between $2.83 billion and $2.87 billion, representing reported growth of 3% to 4%[17] - Organic revenue growth is expected to be between 3% and 5%[17] - Adjusted operating margin is guided to be between 27.9% and 28.1%[17] - Adjusted EPS is projected to be between $4.90 and $5.00[17]

Core Insights - Revvity (RVTY) reported revenue of $664.76 million for the quarter ended March 2025, reflecting a 2.3% increase year-over-year and a surprise of +0.39% over the Zacks Consensus Estimate of $662.17 million [1] - The company's EPS for the quarter was $1.01, up from $0.98 in the same quarter last year, resulting in an EPS surprise of +5.21% compared to the consensus estimate of $0.96 [1] Revenue and Earnings Performance - Organic revenue growth in Life Sciences was 2%, below the average estimate of 6.1% from three analysts [4] - Total organic revenue growth was reported at 4%, exceeding the average estimate of 3.6% from three analysts [4] - Organic revenue growth in Diagnostics was 5%, significantly higher than the average estimate of 1.5% from three analysts [4] Sales Metrics - Net Sales in Life Sciences reached $340.40 million, slightly above the average estimate of $338.13 million from three analysts, with a year-over-year change of +12.3% [4] - Net Sales in Diagnostics were reported at $324.37 million, slightly below the average estimate of $324.78 million from three analysts, representing a year-over-year decline of -6.6% [4] Stock Performance - Revvity's shares have returned -10.7% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - Revvity Inc. reported first-quarter sales of $664.76 million, a decrease from $709.07 million, but exceeding the consensus estimate of $661.18 million [1] - The company achieved an adjusted EPS of $1.01, surpassing the consensus of 95 cents [4] - Adjusted operating income was $170 million, compared to $166 million for the same period last year [4] - The adjusted operating profit margin was 25.6%, slightly up from 25.5% year-over-year [4] Guidance and Forecast - Revvity affirmed its fiscal year 2025 adjusted EPS guidance of $4.90-$5.00, compared to the consensus of $4.94 [2] - The company raised its 2025 sales guidance from $2.8 billion to $2.85 billion, exceeding the consensus of $2.83 billion [2] - The guidance reflects a -0.5% impact from foreign currency exchange and assumes 3%-5% organic revenue growth [2] - The company forecasts a 2025 adjusted operating margin of 27.9%-28.1% [3] Segment Performance - The life sciences segment revenue increased by 1% to $340 million [4] - Organic revenue grew by 2%, while diagnostics sales rose 3% year-over-year to $324 million [4] - Organic diagnostics revenue increased by 5% [4] Market Reaction - Revvity stock rose 5% to $99 during the premarket session following the earnings report [3]

Financial Performance - GAAP earnings per share for Q1 2025 was $0.35, up from $0.21 in Q1 2024, representing a 66.7% increase[4] - Revenue for Q1 2025 was $665 million, a 2% increase from $650 million in Q1 2024, with organic growth of 4%[4][7] - Adjusted earnings per share from continuing operations for Q1 2025 was $1.01, compared to $0.98 in the same period last year, reflecting a 3.1% increase[5] - The company reported adjusted operating income of $170 million for Q1 2025, slightly up from $166 million in Q1 2024[5] - Net income for the three months ended March 30, 2025, was $42,237,000, compared to $26,013,000 for the same period in 2024[27] - Adjusted operating profit margin for Q1 2025 was 25.6%, slightly up from 25.5% in the same period last year[5] - Revenue for the three months ended March 30, 2025, was $664,762,000, an increase of 2% compared to $649,920,000 for the same period in 2024[22] - Adjusted operating income for the same period was $169,911,000, representing an operating margin of 25.6%, slightly up from 25.5% in the prior year[22] Revenue Segments - The Life Sciences segment reported Q1 2025 revenue of $324 million, a 3% increase year-over-year, with organic revenue growth of 5%[6] - The Diagnostics segment achieved Q1 2025 revenue of $340 million, a 1% increase from $337 million in Q1 2024, with organic growth of 2%[8] - The Life Sciences segment generated revenue of $340,395,000, while the Diagnostics segment generated $324,367,000 for the three months ended March 30, 2025[22] Guidance and Projections - Full year 2025 revenue guidance has been raised to a range of $2.83-$2.87 billion, with organic growth guidance reaffirmed at 3-5%[10] - The company reaffirmed its adjusted EPS guidance for the full year 2025 at $4.90-$5.00[10] - Projected organic revenue growth for FY 2025 is estimated to be between 3% and 5%[31] Assets and Liabilities - The company reported total assets of $12,360,724,000 as of March 30, 2025, a slight decrease from $12,392,478,000 at the end of 2024[24] - Cash and cash equivalents at the end of the period were $1,138,687,000, down from $1,164,452,000 at the beginning of the period[28] - Total liabilities were reported at $4,723,594,000, with long-term debt amounting to $3,168,384,000[24] Non-GAAP Measures - The company uses "adjusted earnings per share from continuing operations" to exclude various costs, including amortization of intangible assets and acquisition-related expenses, to better reflect ongoing performance[41] - Management believes that amortization of intangible assets does not accurately reflect ongoing operations, as these charges are fixed post-acquisition[42] - Debt extinguishment costs are excluded from non-GAAP measures as they do not reflect the performance of ongoing operations[42] - Significant litigation matters and settlements are not included in adjusted earnings as they do not represent ongoing operational performance[45] - The company excludes asset impairments from non-GAAP measures, believing they do not accurately reflect ongoing operations[45] - Changes in the value of investments are excluded from adjusted earnings, as management believes these do not reflect ongoing operational performance[45] - The impact of foreign currency changes is excluded to avoid obscuring underlying trends in performance[45] - Management uses non-GAAP measures to evaluate operating performance and communicate financial results to the Board of Directors[47] - The company emphasizes that non-GAAP measures should be viewed alongside GAAP financial measures due to their limitations[46] - Non-GAAP measures may differ from similar measures used by other companies, highlighting the need for careful comparison[46] Operational Performance - The company emphasized strong execution and adaptability to macroeconomic changes as key drivers of performance in Q1 2025[6] - Organic revenue growth from continuing operations was 4%, after accounting for a -1% impact from foreign exchange rates[30] - The company incurred $10,586,000 in significant litigation matters and settlements during the quarter[22]

Core Viewpoint - Revvity (RVTY) is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates consistently in recent quarters [1][2]. Earnings Performance - For the last reported quarter, Revvity achieved earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.36 per share by 4.41% [2]. - In the previous quarter, the company reported earnings of $1.28 per share against an expected $1.13 per share, resulting in a surprise of 13.27% [2]. Earnings Estimates and Predictions - Recent estimates for Revvity have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for Revvity stands at +0.52%, reflecting increased analyst optimism regarding its near-term earnings potential [8]. Zacks Rank and Success Rate - Revvity holds a Zacks Rank of 3 (Hold), which, when combined with a positive Earnings ESP, suggests a high probability of beating consensus estimates, with historical data indicating nearly 70% success in such scenarios [6][8]. Upcoming Earnings Report - The next earnings report for Revvity is anticipated to be released on April 28, 2025 [8].

Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]

Core Viewpoint - The market anticipates Revvity (RVTY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Revvity is expected to post quarterly earnings of $0.96 per share, reflecting a -2% change year-over-year, while revenues are projected to be $662.71 million, up 2% from the previous year [3]. - The consensus EPS estimate has been revised 0.13% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading indicates a likely earnings beat, particularly when combined with a strong Zacks Rank [8]. - For Revvity, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.52%, but the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [10][11]. Historical Performance - Revvity has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +4.41% surprise in the most recent quarter [12][13]. Conclusion - While Revvity does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

Revenue and Financial Performance - Revenue for fiscal year 2024 was $2,755.0 million, an increase of $4.5 million, or less than 1%, compared to fiscal year 2023[146]. - Diagnostics segment revenue increased by $42.7 million, or 3%, to $1,500.9 million, driven by growth in immunodiagnostics and reproductive health[157]. - Life Sciences segment revenue decreased by $38.2 million, or 3%, to $1,254.1 million, primarily due to a decline in instruments and reagents revenue[154]. - Total revenue for the year ended December 29, 2024, was $2.755 billion, a slight increase from $2.751 billion in 2023[220]. - Product revenue decreased to $2.338 billion in 2024 from $2.416 billion in 2023, while service revenue increased to $416.8 million from $334.7 million[220]. - Operating income from continuing operations rose to $346.7 million in 2024, compared to $300.6 million in 2023, reflecting a 15.4% increase[220]. - Net income for 2024 was $270.4 million, a significant decrease from $693.1 million in 2023, primarily due to losses from discontinued operations[220]. - Basic earnings per share from continuing operations increased to $2.31 in 2024 from $1.44 in 2023[220]. Expenses and Margins - Consolidated gross margin decreased by 16 basis points to 55.8% in fiscal year 2024, attributed to an unfavorable product mix and higher product costs[147]. - Consolidated operating margin increased by 166 basis points to 16.5% in fiscal year 2024, supported by productivity initiatives and cost containment[144]. - Research and development expenses decreased by $19.7 million, or 9%, to $196.8 million, representing 7.1% of revenue[149]. - Selling, general and administrative expenses decreased by $28.5 million, or 3%, to $994.1 million, accounting for 36.1% of revenue[148]. Cash Flow and Financing Activities - Net cash provided by continuing operations increased to $665.0 million in fiscal year 2024, up from $279.4 million in fiscal year 2023, reflecting higher income and less cash used for working capital[165]. - The company reported net cash used in financing activities of $1,128.2 million for fiscal year 2024, an increase of $181.1 million compared to $947.1 million in fiscal year 2023[168]. - The company authorized a new stock repurchase program for up to $1.0 billion, replacing the previous program, with $857.2 million remaining available for repurchases as of December 29, 2024[175]. - The company received cash proceeds of $2.27 billion from divestitures, with an additional $75 million expected from the Brand Sale and up to $150 million contingent on future sales by the Purchaser[181]. Tax and Interest Expenses - The effective tax rate for fiscal year 2024 was 10.5%, compared to 1.9% in fiscal year 2023[151]. - Interest and other expense, net, decreased significantly from $117.6 million in fiscal year 2023 to $30.6 million in fiscal year 2024[150]. - The total provision for income taxes for continuing operations was $33.1 million in 2024, compared to $3.5 million in 2023[295]. Assets and Liabilities - As of December 29, 2024, the company had cash and cash equivalents of $1,163.4 million, with $1.5 billion of borrowing capacity available under its senior unsecured revolving credit facility[173]. - Total assets decreased to $12.392 billion in 2024 from $13.565 billion in 2023[226]. - Total stockholders' equity decreased to $7.667 billion in 2024 from $7.873 billion in 2023[226]. - The company’s total liabilities decreased from $4,951,018 thousand in 2023 to $5,609,212 thousand in 2024[230]. Goodwill and Intangible Assets - The company's goodwill balance as of December 29, 2024, was $6.5 billion, with $4.3 billion allocated to the Life Sciences reporting unit[214]. - The fair value of the Life Sciences reporting unit exceeded its carrying value by more than 10% but less than 20% as of November 1, 2024[215]. - Total amortization expense related to amortizable intangible assets was $359.4 million in fiscal year 2024, with estimated future amortization expenses projected to decrease over the next five years[317]. Strategic Initiatives and Future Outlook - The company anticipates an increase in capital expenditures in fiscal year 2025, focusing on enhancing digital capabilities and product innovations[172]. - The company plans to fund its strategic initiatives through a combination of existing cash reserves and internally generated funds from continuing operations[172]. - The company expects to recognize substantially all deferred revenue within 12 months of the balance sheet date[287]. Discontinued Operations - For fiscal year 2024, the company recognized a loss of $12.7 million from discontinued operations, compared to income of $513.6 million in fiscal year 2023[162]. - The operating loss from discontinued operations for the fiscal year ended December 29, 2024, was $37.9 million, compared to an operating income of $68.4 million in 2023[292]. Pension and Benefit Obligations - The company recognized a net periodic pension cost of $10,314,000 for fiscal year 2024, compared to $20,062,000 in 2023[329]. - Accumulated benefit obligations for Non-U.S. increased to $212,120, while U.S. obligations rose to $90,293 as of December 29, 2024[332]. - The discount rate for Non-U.S. plans was 4.19% and for U.S. plans was 5.71% as of year-end measurement[332].